Calithera Biosciences to Report First Quarter 2017

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
46
Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

SOUTH SAN FRANCISCO, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s first quarter 2017 financial results will be released on Tuesday, May 9, 2017.  Company management will host a conference call on Tuesday, May 9, 2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com . The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 18046993.   Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for replay on Calithera’s website for 30 days.

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.  Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents.  CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells.  Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells.  CB-1158 is being developed in collaboration with Incyte Corporation and is currently in a Phase 1 clinical trial.  Calithera is headquartered in South San Francisco, California.  For more information about Calithera, please visit www.calithera.com .

CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 608

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 360

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Mako Hiraizumi Shines with Silver at Japan Triathlon

Updated Category News Views 23

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 149

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 124

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 38

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 467

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 187

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 101

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 481

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading

Top 5 Most Recently Viewed Articles

Homebuyers Benefit as Mortgage Rates Hit New Lows

Updated Category News Views 110

Mortgage Rates See a Significant Drop Recent data shows that mortgage rates have fallen to their lowest point in more than 18 months. This presents a prime opportunity for homebuyers who might be thinking about refinancing their current loans. The drop in rates can be linked to various market dynamics, which has led to a noticeable spike in refinancing activity. Current...

Continue Reading
Cross River Bank Launches Innovative FDIC Sweep Service

Updated Category News Views 195

Introducing Cross River's Automated Sweep Feature Cross River Bank, a pioneering technology infrastructure provider known for its innovative embedded financial solutions, has recently unveiled its automated sweep feature leveraging the IntraFi Cash Service. This groundbreaking service allows Cross River's Banking-as-a-Service (BaaS) clients to access enhanced FDIC...

Continue Reading
Understanding P/E Ratio and Its Importance for PNC Investors

Updated Category News Views 198

Understanding the P/E Ratio for PNC Financial Services Group In today’s trading session, PNC Financial Services Group’s stock is valued at $187.43, reflecting a slight increase of 0.87%. Looking at the broader picture, the stock of PNC Financial Services Group Inc. has risen by an impressive 4.19% over the past month and a remarkable 63.74% in the past year. These...

Continue Reading
Grace Therapeutics Sees Positive Outcomes and Business Growth

Updated Category News Views 224

Grace Therapeutics Reports Promising Progress and Financial Update Grace Therapeutics, Inc. (NASDAQ: GRCE), a biopharmaceutical company dedicated to advancing treatment solutions, has just shared significant news regarding its fiscal operations and pivotal clinical advancements. The company focuses on developing GTx-104, a promising injectable formulation of nimodipine...

Continue Reading
Jordan G. Welch's Worship Culture Tour: A Transformative Experience

Updated Category News Views 643

Jordan G. Welch's Worship Culture Tour Unleashes New Dimensions in Worship The Worship Culture Tour is set to launch with a vibrant focus on creating an immersive worship experience that extends beyond traditional confines. This exciting two-day event will guide participants through a journey of spiritual growth across multiple cities, inviting people from all walks of...

Continue Reading